Adipotide (FTPP): A Vasculature-Targeted Proapoptotic Peptide

Research summary. Adipotide — also referred to as FTPP (Fat-Targeted Proapoptotic Peptide) — is a synthetic chimeric peptidomimetic engineered to selectively trigger apoptosis in the vasculature supporting white adipose tissue. Rather than acting on adipocytes themselves, the molecule disrupts the capillary network that perfuses fat depots, leading to reductions in adipose mass in preclinical models.

Molecular profile

• Sequence: CKGGRAKDC-GG-(KLAKLAK)₂
• Molecular formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular weight: ~2611.4 g/mol
• Architecture: A homing domain (CKGGRAKDC) fused via a glycine-glycine linker to a proapoptotic D-amino-acid sequence, (KLAKLAK)₂

The design pairs two functional modules. The CKGGRAKDC homing peptide binds prohibitin, a receptor enriched on the endothelial surface of white-adipose-tissue capillaries. The (KLAKLAK)₂ effector, once internalised, disrupts mitochondrial membranes and initiates programmed cell death. The chimera therefore behaves as a vascular-targeted apoptotic warhead rather than a systemic cytotoxin.

Mechanism of action

Adipotide exploits the observation that vascular endothelial cells in different tissues display distinct surface markers — a "vascular ZIP code" mapped extensively by the Arap–Pasqualini laboratory using phage-display screening. Prohibitin is selectively expressed on adipose endothelium, allowing CKGGRAKDC to localise the cytotoxic cargo. Internalisation delivers (KLAKLAK)₂ to the mitochondrial outer membrane of the targeted endothelial cell, where it forms amphipathic structures that compromise membrane integrity, release cytochrome c, and trigger caspase-mediated apoptosis. Loss of capillary support is followed by resorption of the surrounding adipocytes.

Preclinical research highlights

Initial proof of concept (murine). The seminal report by Kolonin and colleagues demonstrated that systemic administration of the prohibitin-targeted proapoptotic peptide produced rapid, selective ablation of white adipose tissue in obese mouse models, with normalisation of metabolic parameters and no detectable effect on lean tissue compartments [1].

Non-human primate model. A subsequent translational study by Barnhart and colleagues evaluated the same chimera in spontaneously obese rhesus macaques. Treated animals exhibited marked reductions in body weight and BMI, decreased adiposity on imaging, and improvements in insulin sensitivity as measured by intravenous glucose tolerance testing. A reduction in caloric intake was also observed in treated animals, suggesting a possible behavioural or hypothalamic component to the response that has not been fully characterised [2].

Oncology-adjacent investigations. Because prohibitin is also upregulated on the vasculature of certain solid tumours, follow-on work has explored Adipotide-class molecules as candidates in vascular-targeted oncology research. These investigations remain preclinical.

Safety signals from preclinical work

The non-human primate work also reported reversible alterations in renal function during dosing, attributable to the kidney's role in clearing the peptide, with parameters returning toward baseline after washout. These findings have shaped the cautious pace of any further translational evaluation and underscore that Adipotide is a research compound — not an approved therapeutic.

Current research status

Adipotide remains an investigational research peptide. It has not received marketing authorisation from the U.S. Food and Drug Administration or any comparable regulatory body. Published work to date is confined to in-vitro assays and animal models (rodent and non-human primate). Active areas of academic interest include refining the homing domain to minimise off-target uptake, exploring alternative effector cargoes attached to the same prohibitin-targeting scaffold, and characterising the mechanism behind the appetite-suppressive signal observed in primates.

Key takeaways for researchers

• Adipotide is a chimeric peptidomimetic, not a conventional bioactive peptide — its activity depends on the synergy between a vascular homing domain and a proapoptotic effector.
• Reported activity is mediated through endothelial apoptosis in adipose-supporting capillaries, not direct lipolysis.
• All efficacy data are derived from preclinical models. No human clinical efficacy or safety data exist in the public literature.
• Renal handling of the peptide warrants attention in any in-vivo experimental design.

References

1. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine. 2004;10(6):625–632.
2. Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine. 2011;3(108):108ra112.

---

This article is provided for educational and research purposes only. Adipotide (FTPP) is a research-grade compound. It is not a drug, supplement, or approved therapeutic agent, and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.